tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

EXEL Stock Latest News

Exelixis Launches Special Equity Award Program
Company AnnouncementsExelixis Launches Special Equity Award Program
3d ago
8K
EXEL
Exelixis’s Strategic Positioning and sNDA Approval for Cabometyx Drive Buy Rating
PremiumRatings
Exelixis’s Strategic Positioning and sNDA Approval for Cabometyx Drive Buy Rating
7d ago
EXEL
Exelixis Buy Rating: FDA Approval of Cabozantinib and Growth Catalysts Drive Positive Outlook
PremiumRatings
Exelixis Buy Rating: FDA Approval of Cabozantinib and Growth Catalysts Drive Positive Outlook
7d ago
EXEL
Exelixis Gains Buy Rating from Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market
PremiumRatings
Exelixis Gains Buy Rating from Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market
8d ago
EXEL
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi
PremiumThe Fly
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi
8d ago
EXEL
Exelixis announces FDA approval of Cabometyx treatment groups
PremiumThe FlyExelixis announces FDA approval of Cabometyx treatment groups
8d ago
EXEL
FDA approves cabozantinib for adults and pediatric patients with pNET and epNET
Premium
The Fly
FDA approves cabozantinib for adults and pediatric patients with pNET and epNET
8d ago
EXEL
Exelixis to present positive preclinical data across pipeline portfolio at AACR
Premium
The Fly
Exelixis to present positive preclinical data across pipeline portfolio at AACR
9d ago
EXEL
Exelixis price target raised to $40 from $38 at RBC Capital
PremiumThe Fly
Exelixis price target raised to $40 from $38 at RBC Capital
21d ago
EXEL
Wells Fargo downgrades Exelixis, says take profits after rally
PremiumThe Fly
Wells Fargo downgrades Exelixis, says take profits after rally
1M ago
EXEL
Exelixis downgraded to Equal Weight from Overweight at Wells Fargo
PremiumThe Fly
Exelixis downgraded to Equal Weight from Overweight at Wells Fargo
1M ago
EXEL
Exelixis announces final five-year follow-up results from CheckMate -9ER
PremiumThe Fly
Exelixis announces final five-year follow-up results from CheckMate -9ER
2M ago
EXEL
Exelixis Hold Rating Maintained Amidst Stable Financials and Awaited Trial Data
PremiumRatingsExelixis Hold Rating Maintained Amidst Stable Financials and Awaited Trial Data
2M ago
EXEL
Exelixis Earnings Call: Positive Growth and Ambitious Goals
Premium
Company Announcements
Exelixis Earnings Call: Positive Growth and Ambitious Goals
2M ago
EXEL
Exelixis price target raised to $38 from $34 at TD Cowen
Premium
The Fly
Exelixis price target raised to $38 from $34 at TD Cowen
2M ago
EXEL
Exelixis price target raised to $36 from $30 at Stifel
PremiumThe Fly
Exelixis price target raised to $36 from $30 at Stifel
2M ago
EXEL
Exelixis price target raised to $29 from $25 at Barclays
PremiumThe Fly
Exelixis price target raised to $29 from $25 at Barclays
2M ago
EXEL
Exelixis price target raised to $38 from $37 at Piper Sandler
PremiumThe Fly
Exelixis price target raised to $38 from $37 at Piper Sandler
2M ago
EXEL
Hold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market Opportunities
PremiumRatings
Hold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market Opportunities
2M ago
EXEL
Exelixis’s Growth Potential Bolstered by Cabozantinib Expansion and Promising New Drug Developments
PremiumRatingsExelixis’s Growth Potential Bolstered by Cabozantinib Expansion and Promising New Drug Developments
2M ago
EXEL
Exelixis price target raised to $45 from $38 at Citi
Premium
The Fly
Exelixis price target raised to $45 from $38 at Citi
2M ago
EXEL
Positive Outlook for Exelixis Driven by Promising Developments in Zanzalintinib and Cabozantinib
Premium
Ratings
Positive Outlook for Exelixis Driven by Promising Developments in Zanzalintinib and Cabozantinib
2M ago
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >